Major risk factors for cardiovascular diseases are hypertension, diabetes mellitus, dyslipidaemia, smoking and obesity. In this review article, we have tried to discuss the updated management of each major risk factor. 
Introduction
Cardiovascular risk factor is a condition that is associated with an increased risk of developing cardiovascular disease 1 . It is not always obvious that person with one cardiovascular risk factor may develop the disease. But it increases the probability. On the contrary, person who does not have any risk factor may develop the cardiovascular disease 2 . With rare exceptions, all heart attacks are caused by atherosclerosis of the coronary arteries resulting from fatty deposits called plaque 3 . Atherosclerosis also plays same role in other vascular diseases like Stroke, Transient Ischemic Attack (TIA) and peripheral vascular diseases 4, 5 . Framingham heart study was the milestone study that revealed the cause of atherosclerotic heart disease. The first director of that historical Framingham study Dr. William Kannel concluded that multiple factors are responsible for atherosclerotic changes of the vessel and these factors together termed " cardiovascular risk factors" 8, 12, 13 .
CVS risk factors:
Fixed:
• 3, 7, 10 . By lowering the blood pressure TOD can be prevented. In clinical trials, antihypertensive therapy has been associated with a 20% to 25% reduction in myocardial infarction as well as a 35% to decrease in stroke and a 50% decrease in heart failure. "All patients with known ischemic heart disease should be treated to achieve blood pressure of less than 140/90 mm of Hg and it should be less than 130/80 mm of Hg in patients with diabetes or renal disease" says Joint National Committee (JNC) seventh report on prevention, detection, evaluation and treatment of high blood pressure 3 . They gave a clear-cut treatment protocol that includes nonpharmacological intervention and pharmacological approach. Non-pharmacological approach-the life style modification is the corner stone of management of hypertension. Not only incase of hypertension management, life style modification basically is the top charted treatment approach for all sorts of cardiovascular events.
Pre-hypertension condition requires only life style modification.
Loose weight if overweight, increase aerobic physical activity (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) 2 . This global pandemic principally involves type 2 diabetes. Type 2 diabetes commonly occurs in subjects who are obese and insulin-resistant, but these two factors alone insufficient to cause DM unless accompanied by impaired beta cell function. Genetic factors are important in the etiology of type-2 diabetes. The majority of cases of type-2 diabetes are multifactor in nature, with interaction of environmental and genetic factors. The nature of the genetic contribution is largely unknown 26 . But it is evident that several genes are involved. Genes would not be sufficient to cause type 2 diabetes directly. Genome-wide searches have identified susceptibility genes on chromosome 1 q. 12 q and 20q. But the underlying genes have not been identified. Molecular genetics has allowed the identification of certain specific and clinically identifiable forms of diabetes, which are caused by single gene defects. However these subtypes, such as maturity onset diabetes of the young (MODY) are uncommon and constitute less than 5% of all cases of diabetes 27 .
Retrospective analysis of the birth weight of males born in England in the 1930s has demonstrated an inverse relation ship between weight at birth and at 1 year, and the development of type 2 diabetes in late adulthood. Smoking during pregnancy has also been implicated. Age is an important risk factor for type 2 diabetes. In Britain over 70% of all cases of diabetes occur after the age of 50 years. Type 2 diabetes in principally a disease of the middle aged and elderly, affecting 10% o the population over the age of 65.
The insulin-secreting cells of the pancreatic islets may be unable to meets this increased demand in women genetically predisposed to develop diabetes. The term 'gestational diabetes' refers to hyperglycemia occurring for the first time during pregnancy.
Management of Diabetes:
Three methods of treatment available for diabetic patients are: diet alone, oral hypoglycaemic drugs, and insulin. Approximately 50% of new cases of diabetes can be controlled adequately by diet alone 20-30% require insulin 2, 30 .
Oral Hypoglycemic Drugs: Various drugs are effective in reducing hyperglycaemia in patients with type 2 diabetes. The sulphonylureas and the biguanides have been the mainstay of treatment for many years but novel agents are now available, such as the insulin-enhancing agents-the thiazolidinediones, the alpha-glucosidase inhibitors 2, 29 .
Sulphonylureas are valuable in the treatment of non-obese patients with type 2 diabetes who fail to respond to dietary measures alone. Although sulphonylureas will lower the blood glucose concentration of obese patients with type 2 diabetes, it is often associated with hypoglycemia and an increase in weight, which will increase insulin resistance and eventually aggravate the total disability. This leads to secondary failure to respond to the drugs, and progression to treatment with insulin. Of the second-generation sulphonylureas, gliclazide and glipizide cause few side effects, but glibenclamide is prone to induce severe hypoglycemia and should be avoided in the elderly. Newer long-acting preparations such as glimeperide and a modified-release from of gliclazide can be administered once daily with no apparent increased risk of hypoglycemia.
Metfromin is the only biguanide available. The long-term benefit of metformin was shown in the United Kingdom Prospective Diabetes Study (UKPDS) but it is less widely used than the sulphonylureas because of a higher incidence of side effects. It is preferred for the obese patient. The hypoglycaemic effect of metformin is synergistic with that of the sulphonylurea drugs; the two can be combined when either alone has proved inadequate. Its use is contraindicated in patients with impaired renal or hepatic function and in those who take alcohol 46, 47 .
Acarbose or miglitol (Alpha-Glucosidase Inhibitors) is available. Both lower post-prandial blood glucose and modestly improve overall glycaemic control. They can be combined with a sulphonylurea. The main side effects are flatulence, abdominal bloating and diarrhoea. Rosiglitazone or pioglitazone (Thiazolidinediones) should be prescribed with either a sulphonylurea or metformin; they have few side-effects, although they promote weight gain and fluid retention and are contraindicated in people who have cardiac failure. Meglitinides and Amino acid Derivatives are oral prandial glucose regulators. Repaglinide directly stimulates endogenous insulin secretion and is taken immediately before food. It is less likely to cause hypoglycemia than sulphonylureas. In diabetics who are requiring increasing doses of a sulphonylurea or biguanide, either alone or in combination with each other or with thiazolidinedione, the introduction of a single dose of an intermediate-acting insulin (usually isophane), administered at bedtime, may improve glycaemic control and delay the development of overt pancreatic beta cell failure. The exogenous insulin suppresses hepatic glucose output during the night and lowers fasting blood glucose. This treatment is ineffective in diabetic patients who have no residual endogenous insulin secretion 48 .
According to United Kingdom Perspective Diabetic Study (UKPDS), 50% of newly presenting patients with type 2 diabetes already have one or more complications at diagnosis and among them the prevalence of Hypertension is 35%, Abnormal E.C.G. 18%, Stroke or TIA 1% and MI 1%. So treating this group of patients needs more attention of the clinicians in terms of reasonable approach 49, 50 .
Patients having hypertension with diabetes should be treated with a goal systolic BP of <130 and diastolic BP of <80 mm of Hg. Life style modification, not to be waited more than three months, should be advised for the patients having systolic BP ranging from 130-139 and the diastolic BP ranging from 80-89 mm of Hg. Therapeutic treatment should be advised for the patient in whom systolic BP is>140 and diastolic BP is >90 mm of Hg along with life style modification. Unless contraindicated the drug of choice for these patients is Ramipril 12, 20 .
DM with dyslipidaemia:
Prevalence is 30-50% and the common pattern is elevated triglyceride & decreased HDL cholesterol. This is a strong predictor of CHD. According to NCEP, LDL-C is also a potent predictor for CVD. Dyslipidaemia with DM-Risk category based on lipid levels is, High (LDL>130, HDL>30 and triglyceride>400), Borderline (LDL>120-29, HDL>35-45 and triglyceride>200-399) and Low (LDL<100, HDL>45 and triglyceride<200) 12, 13 . 
Obesity: may be defined as a body mass index (BMI) greater than 30. BMI = Weight in Kg / (Height in Meter) 2 . Two types of Obesity-Android or abdominal type and Gynecoid or buttock type. Male having > 40 inches and female having >35 inches waist are considered as obese. Several causes of obesity include genetic, social, behavioral, cultural, psychological, metabolic and drugs. LEPTIN a hormone discovered in 1994 regulate adipose proliferation and modulate eating behavior. 80% of people with type-II DM are obese. It is a major factor in insulin resistance & determinant for choice of appropriate therapy 40, 41, 42 .
Managing obesity is a very difficult task. 90% people who attempt to lose weight gain it all back. Reasonable goal is to lose 10% body wt over a 6 months period. Patients with BMI 27-35 should lose half kg per week. Patients with BMI above 35 should lose one kg per week.
Essential mode of therapy should be included (i) Counseling (ii) Restriction of calories (1200 -1800 Kcal) (iii) Life style modification and (iv) Physical activity (i.e. weight loss & maintenance) 4, 6 Pharmacotherapy: Most of the drugs used in the management of obesity are not ideal. Packa-day smokers are at twice the risk for heart attack than non-smokers and smoking two or more packs a day triple the risk. Sudden death increases more than 10 folds in men who smoke 12 . Smoking cigarette that are low in nicotine and tar does not decrease the risk of heart disease. Heart attack victims are four times more likely to die if they smoke. Female smokers who use oral contraceptives are 39 times more likely to have heart attack and 22 times more likely to have a stroke. Environmental tobacco smoke or "second hand smoke" in high concentrations has been linked to CVD in nonsmokers 13 .
Behavioral factor-Type A personality: There is debate. Type A personalities are coronary prone. Sense of time pressure, chronic impatience, always in hurry and excessive hostility tends to become upset easily for funny cause.
Conclusion
Cardiovascular risk management is a very difficult task when multi component present in one person. Risk reduction involves intervention in each area in which risk is identified. Present recommendation is for proper control and management of HTN, DM, dyslipidaemia, obesity and cessation of smoking. For these non-contagious but killer diseases national as well as global economic burden is increasing.
Considering the socio-economic condition in the world suggests that prevention through 'life style modification' is the universal 'vaccine' in the management of cardiovascular risk factors. Role of responsible physicians' judgment remains paramount for motivation, empathy to the patients, selecting the drugs and adherence to the treatment for the management of this overwhelming condition. 
